Monitoring for post-injection delirium/sedation syndrome with long-acting olanzapine during the COVID-19 pandemic.

Field	Value	Language
dc.contributor.author	Siskind, Dan	en
dc.contributor.author	Northwood, Korinne	en
dc.contributor.author	Berk, Michael	en
dc.contributor.author	Castle, David	en
dc.contributor.author	Galletly, Cherrie	en
dc.contributor.author	Harris, Anthony	en
dc.date.accessioned	2020-06-18
dc.date.available	2020-06-18
dc.date.issued	2020	en
dc.identifier.uri	https://hdl.handle.net/2123/22545
dc.description.abstract	We included all 74,960 olanzapine LAI dispensings listed in the Pharmaceutical Benefits Schedule (PBS) database from the introduction of olanzapine LAI in January 2010 until the end of January 2020. Adverse event reports for all olanzapine formulations (and the subset of olanzapine LAI) were drawn from Australian Therapeutic Goods Association Database of Adverse Event Notifications (DAEN).	en
dc.language.iso	en	en
dc.rights	Other
dc.subject	COVID-19	en
dc.subject	Coronavirus	en
dc.title	Monitoring for post-injection delirium/sedation syndrome with long-acting olanzapine during the COVID-19 pandemic.	en
dc.type	Article	en
dc.identifier.doi	10.1177/0004867420927465
usyd.faculty	Faculty of Science	en

Associated file/s

There are no files associated with this item.